VIDEO: Psoriasis patients can switch medications, still receive effective treatment

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-17 inhibitor ixekizumab from the Maui Derm 2024 meeting.

Chovatiya, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, discussed a 6-month, real-world study of patients who switched from an IL-23 inhibitor to ixekizumab (Taltz, Eli Lilly & Co.).

“(The data suggests) that whatever order you seem to choose with your medications, as long as you’re sort of switching between mechanisms of action, you can actually help patients achieve very high endpoints for efficacy in a very safe way,” Chovatiya said.